On the basis of structural similarities between various calcium channel antagonists (Verapamil or Diltiazem) a novel series of derivatives belonging to the dibenzodiazocinedione family were designed and synthesised to obtain drugs able to revert multidrug resistance (MDR). X-ray structure studies and conformational analysis of 5,11-dibenzyldibenzo[b,f][1,5]diazocine-6,12-dione were performed. Molecular modelling results have shown that observed reversal activity of this new derivative could refer to a thermodynamically limited concentration in a peculiar (extended) conformation.